Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + S-1 + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Pembrolizumab + S-1 + oxaliplatin is a combination regimen used primarily in the first-line treatment of advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinoma that is PD-L1-positive and HER2-negative. Pembrolizumab is a humanized monoclonal antibody targeting programmed death 1 (PD-1), acting as an immune checkpoint inhibitor to enhance anti-tumor immune responses. S-1 is an oral fluoropyrimidine derivative combining tegafur (a prodrug of 5-fluorouracil), gimeracil, and oteracil potassium; it acts as an antimetabolite chemotherapeutic agent inhibiting thymidylate synthase. Oxaliplatin is a platinum-based chemotherapeutic that induces DNA crosslinking and apoptosis in cancer cells. The combination has shown encouraging efficacy and manageable safety in phase IIb clinical trials for advanced G/GEJ cancer[1][2][5][7].
- Brand names
- Keytruda + S-1 + Eloxatin
- Other names
- SOX plus pembrolizumabSOX/pembrolizumabpembrolizumab/SOX
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on pembrolizumab + S-1 + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + S-1 + oxaliplatin.